KEWAUNEE SCIENTIFIC CORP /DE/
Kewaunee Scientific designs, manufactures and installs laboratory, healthcare and technical furniture and infrastructure products. Its offerings include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, benches, biological safety cabinets, and epoxy resin work surfaces and sinks. Through Nu Aire, it also offers CO2 incubators, ultralow freezers, airflow products, animal handling equipment and pharmacy compounding isolators. The products serve customers including research laboratories, educational and healthcare institutions, government entities and manufacturing facilities. Kewaunee operates through its Lab Products Group and International segments. It sells mainly through customer purchase orders and contracts, received directly or through dealers, subsidiaries in Singapore and India, and a national distributor. Its international subsidiaries also provide facility design, detailed engineering construction and project management for laboratories, from planning through testing and commissioning. Kewaunee is headquartered in Statesville, North Carolina.
No SEC Form 4 filings for $KEQU in the last 30 days.
See all $KEQU insider activity →Kewaunee Scientific (KEQU) agreed to acquire Nycom, a major lab dealer, for $55M, with $20M in notes, $5M in stock, and the rest in cash. The deal aims to combine Nycom's project expertise with Kewaunee's manufacturing, enhancing lab solutions. Nycom's leadership will join Kewaunee's board and management. The transaction is expected to close in Q4 2027, pending approvals.
Kewaunee Scientific (KEQU) reported Q1 FY2027 results: sales $66.3M (-6.7% YoY), net earnings $1.7M (-34.7% YoY), EBITDA $4.5M (-34.7% YoY). Backlog grew to $169M. International segment earnings rose 23.5% despite lower sales. Long-term debt fell to $13.8M. CEO cited strong quoting activity and strategic execution.
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KEQU (KEWAUNEE SCIENTIFIC CORP /DE/). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent KEQU coverage spans insider activity, earnings and mergers & acquisitions.
The acquisition expands Kewaunee's market reach and could boost earnings, but share dilution may temper upside.
Earnings miss and declining sales may pressure the stock, while improved backlog and lower debt provide some support.
Earnings miss may pressure the stock short term; backlog growth offers upside potential.
Routine governance filing with no material impact on valuation.
The announcement sets the date for the upcoming earnings release, providing a timing cue but no new financial data.
AlphAI scores every news story that mentions KEQU with an AI model for sentiment and relevance, and aggregates insider trades from KEWAUNEE SCIENTIFIC CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kewaunee Scientific (KEQU) agreed to acquire Nycom, a major lab dealer, for $55M, with $20M in notes, $5M in stock, and the rest in cash. The deal aims to combine Nycom's project expertise with Kewaunee's manufacturing, enhancing lab solutions. Nycom's leadership will join Kewaunee's board and management. The transaction is expected to close in Q4 2027, pending approvals.
2 min readKewaunee Scientific (KEQU) reported Q1 FY2027 results: sales $66.3M (-6.7% YoY), net earnings $1.7M (-34.7% YoY), EBITDA $4.5M (-34.7% YoY). Backlog grew to $169M. International segment earnings rose 23.5% despite lower sales. Long-term debt fell to $13.8M. CEO cited strong quoting activity and strategic execution.
2 min readKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu
2 min readKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On August 26, 2026, Kewaunee Scientific Corporation (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on the matters set forth below
1 min readKewaunee Scientific (NASDAQ: KEQU) will release its Q1 fiscal 2027 results on September 9, 2026, after market close. The company designs and manufactures laboratory and healthcare furniture, with operations in the U.S. and internationally. It also includes forward-looking statements about risks and uncertainties.
1 min readPhillips Elizabeth D (SVP, People & Culture) sold (to issuer) 4,995 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.18M total) on 2026-06-30.
2 min readNoble Ryan S. (SVP, Sales & Marketing Dev) sold (to issuer) 3,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.11M total) on 2026-06-30.
1 min readBatdorff Douglas J. (SVP, Manufacturing Operations) sold (to issuer) 5,609 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.20M total) on 2026-06-30.
2 min readGardner Donald T. III (Chief Financial Officer) sold (to issuer) 12,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.44M total) on 2026-06-30.
2 min readHULL THOMAS DAVID III (President & CEO) sold (to issuer) 17,000 shares of KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) at $36.25 ($0.62M total) on 2026-06-30.
2 min read
